Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA4 | P22748 | 2/20 | 0.69 |
| ▸ | CA6 | P23280 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010958 | 1.00 | TPMT (0.69) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL27542053 | 0.93 | TPMT (0.61) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL6436867 | 0.86 | CYP1A2 (0.68) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL410669 | 0.85 | CA1 (0.69) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL7943307 | 0.85 | ALDH1A1 (0.54) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL31704508 | 0.83 | MAPT (0.62) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL29375601 | 0.83 | TSHR (0.48) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL29375569 | 0.83 | MAPK1 (0.58) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1171023 | 0.83 | MAPT (0.62) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL6440090 | 0.83 | TSHR (0.48) | TPMTCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896701-A | Synthesis process of Hsp90 inhibitor KU-177 | 南京中医药大学 | 2022-01-07 | — | — | CN | claimed |
| EP-1007528-B1 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | ADVANCED LIFE SCIENCES INC (US) | 2003-11-26 | — | — | EP | claimed |
| US-6225481-B1 | REACTING 6-IODO-5,7,4'-TRIMETHOXYFLAVONE AND 5,7-4'-TRIMETHOXY-3'-(TRIMETHYLSTANNYL)FLAVONE IN PRESENCE OF PALLADIUM COMPOUND AND BASE TO PRODUCE ROBUSTAFLAVONE HEXAMETHYL ETHER, DEMETHYLATING TO PRODUCE ROBUSTAFLAVONE | ADVANCED LIFE SCIENCES, INC. | 2001-05-01 | — | — | US | claimed |
| EP-1007528-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999010292-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | DART NEUROSCIENCE LLC (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| EP-3584239-B1 | O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-09-11 | — | — | EP | disclosed |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117430609-B | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-05-24 | — | — | CN | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117430609-A | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-01-23 | — | — | CN | disclosed |
| EP-1079821-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| CN-1274354-A | Robustaflavone, intermediates and analogues and method for prepn. method | MEDICHEM RES INC (US) | 2000-11-22 | — | — | CN | disclosed |
| EP-1007528-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999059570-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999010292-A2 | ROBUSTAFLAVONE, INTERMEDIATES AND ANALOGUES AND METHOD FOR PREPARATION THEREOF | MEDICHEM RESEARCH, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | TPMT 208/4885CA12 4496/4885CA1 4128/4885 |
| US-20250092047-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | TPMT 965/4885CA12 3748/4885CA1 2362/4885 |
| US-12630556-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors | PDE1A, PDE12, PDE1B | TPMT 130/4885CA12 4135/4885CA1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.